This is further validated in TARGET-AML BM diagnosis samples showing significantly (P=1.3e-05) higher ARMH1 expression in the high-risk cytogenetic subtypes (i.e., MLL) compared to standard-risk [e.g., RUNX1, inv (16)] (Figure 1G). This evidence concerns the gene RUNX1 and acute myeloid leukemia.